(Q44649986)

5 December 2017

title

A multicenter phase II study of gemcitabine and oxaliplatin for malignant pleural mesothelioma (English)

1 reference

5 December 2017

A Multicenter Phase II Study of Gemcitabine and Oxaliplatin for Malignant Pleural Mesothelioma (English)

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

31 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

31 March 2024

author name string

Wolfgang Schutte

1

1 reference

5 December 2017

Thomas Blankenburg

2

1 reference

5 December 2017

Kathrin Lauerwald

3

1 reference

5 December 2017

Jens Schreiber

4

1 reference

5 December 2017

Ines Bork

5

1 reference

5 December 2017

Bettina Wollscgkaeger

6

1 reference

5 December 2017

Dorothea Treutler

7

1 reference

5 December 2017

Claus-Peter Schneider

8

1 reference

5 December 2017

Reiner Bonner

9

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

full work available at URL

5 December 2017

https://api.elsevier.com/content/article/PII:S1525730411702960?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

https://api.elsevier.com/content/article/PII:S1525730411702960?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

31 March 2024

1 reference

5 December 2017

volume

4

1 reference

5 December 2017

issue

5

1 reference

5 December 2017

page(s)

294-297

1 reference

Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province

5 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Chemotherapy in malignant pleural mesothelioma. A review.

31 March 2024

2

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group

31 March 2024

4

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis

31 March 2024

5

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B.

31 March 2024

6

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study

31 March 2024

8

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

A multicentre phase II study of cisplatin and gemcitabine for malignant mesothelioma.

31 March 2024

9

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

One-sample multiple testing procedure for phase II clinical trials

31 March 2024

12

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

31 March 2024

15

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Carboplatin and gemcitabine chemotherapy for malignant pleural mesothelioma: a phase II study of the GSTPV

31 March 2024

17

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

Phase I, dose-finding, and pharmacokinetic study of raltitrexed combined with oxaliplatin in patients with advanced cancer

31 March 2024

19

1 reference

https://api.crossref.org/works/10.3816/CLC.2003.N.009

31 March 2024

Identifiers

1 reference

5 December 2017

1 reference